Linifanib

Drug Overview

Linifanib (also known as ABT-869) is a powerful, experimental cancer medicine that belongs to the class of Targeted Therapies. In the medical world, it is often called a “Smart Drug” because it is designed to seek out and block specific signals that cancer cells use to grow and survive. Unlike traditional chemotherapy that attacks all fast-growing cells, Linifanib focuses on the biological “engines” that drive tumor expansion.

This drug is specifically a multi-target kinase inhibitor. Its primary goal is to cut off the nutrient supply to a tumor—a process known as starving the cancer—while also stopping the cancer cells from multiplying. Because it can be taken as a pill, it offers a convenient option for patients participating in clinical trials around the world, particularly those with liver or lung cancers.

• Generic Name: Linifanib
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Multi-kinase Inhibitor; Tyrosine Kinase Inhibitor (TKI); Angiogenesis Inhibitor
• Route of Administration: Oral (Tablet/Capsule)
• FDA Approval Status: Investigational (Not yet FDA approved for general use)

What Is It and How Does It Work? (Mechanism of Action)

To understand how Linifanib works, imagine a tumor is like a growing city. To expand, the city needs two things: new roads to bring in food (blood vessels) and constant construction signals (growth factors). Linifanib acts like a “master switch” that shuts down both.

At the molecular level, Linifanib targets and binds to specific proteins on the surface of cells called Tyrosine Kinases. It focuses on two main “communication lines”:

1. VEGF Receptors (Vascular Endothelial Growth Factor): These receptors are the “road builders.” When activated, they tell the body to grow new blood vessels toward the tumor (angiogenesis). Linifanib blocks these receptors (VEGFR-1, 2, and 3), effectively cutting off the tumor’s blood and oxygen supply.
2. PDGF Receptors (Platelet-Derived Growth Factor): These act like the “construction workers.” They signal cells to divide and move. By blocking the PDGFR-beta family, Linifanib stops cancer cells from replicating and spreading.

By sitting in the “binding pocket” of these receptors, Linifanib prevents energy molecules (ATP) from starting the signaling chain. This leads to apoptosis, which is a scientific term for “programmed cell death,” where the cancer cell eventually shrivels and dies because it can no longer receive instructions to live.

FDA-Approved Clinical Indications

As an investigational drug, Linifanib does not yet have standard FDA-approved uses. However, it is being utilized in clinical trials for the following conditions:

Oncological Uses (Investigational)

• Hepatocellular Carcinoma (HCC): Advanced liver cancer that cannot be removed by surgery.
• Non-Small Cell Lung Cancer (NSCLC): Used in patients where other treatments have stopped working.
• Advanced Solid Tumors: Various cancers that have spread to other parts of the body.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Linifanib is taken by mouth. Because it is still in the testing phase, doctors calculate the dose carefully based on a patient’s weight or body surface area to ensure safety.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Since the liver processes this drug, patients with liver issues may require a lower dose (e.g., 0.10 mg/kg) to prevent the drug from building up to toxic levels.
• Renal (Kidney) Insufficiency: Specific adjustments are not yet standardized, but patients are monitored closely for protein in their urine.

Clinical Efficacy and Research Results

Clinical data from recent years (2020–2025) has focused on how Linifanib compares to existing treatments like Sorafenib.

• Liver Cancer (HCC) Results: In Phase II and III trials, Linifanib showed a “non-inferior” survival rate compared to standard care. This means it worked just as well as existing drugs, with some patients showing better tumor shrinkage (response rates).
• Disease Progression: Numerical data indicates that for patients with advanced liver cancer, the median Progression-Free Survival (PFS) was approximately 5.4 months in specific trial groups.
• Tumor Shrinkage: Clinical studies reported an Objective Response Rate (ORR) of about 10-13% in lung and liver cancer trials, which is considered significant for patients with very advanced disease.

Safety Profile and Side Effects

Like all “Smart Drugs” that block blood vessel growth, Linifanib has a specific set of side effects related to how it affects the body’s circulation.

Black Box Warning:

None. (Investigational drugs do not yet have formal Black Box Warnings, but similar drugs in this class carry warnings for severe bleeding and heart issues).

Common Side Effects (>10%)

• Hypertension: High blood pressure is the most common side effect.
• Fatigue: Feeling unusually tired or weak.
• Diarrhea: Frequent loose stools.
• Palmar-Plantar Erythrodysesthesia: Also known as Hand-Foot Syndrome (redness, pain, or peeling on the palms and soles).
• Proteinuria: Protein in the urine, which can affect the kidneys.

Serious Adverse Events

• Hemorrhage: Serious internal or external bleeding.
• Gastrointestinal Perforation: A rare but serious tear in the stomach or intestine.
• Heart Failure: Decreased ability of the heart to pump blood.

Management Strategies

• Blood Pressure Monitoring: Patients must check their blood pressure daily. If it gets too high, doctors will prescribe blood pressure medicine.
• Dose Breaks: If side effects become too strong, the doctor may stop the drug for a few days to allow the body to recover.

Research Areas

Linifanib is currently a major focus in Immunotherapy research. Scientists are exploring if Linifanib can “prime” a tumor to be more easily seen by the immune system. By cutting off the tumor’s messy blood supply, the drug might make the tumor environment “cleaner,” allowing Checkpoint Inhibitors (another type of immunotherapy) to enter and kill the cancer more effectively. There is also early-stage interest in how these inhibitors might affect Cancer Stem Cells, the “seeds” that cause cancer to grow back after treatment.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Baseline Blood Pressure: To ensure your heart can handle the treatment.
• Urinalysis: To check for existing protein levels in the urine.
• Liver Function Tests (LFTs): To determine the starting dose.

Precautions During Treatment

• Monitor Your Skin: Use thick, fragrance-free moisturizers on your hands and feet to prevent Hand-Foot Syndrome.
• Check Your Pressure: Keep a log of your blood pressure readings at home.

“Do’s and Don’ts” List

• Do stay well-hydrated to help your kidneys.
• Do tell your doctor immediately if you notice unusual bruising or bleeding.
• Don’t take any new over-the-counter supplements without asking your oncology team.
• Don’t skip doses, but if you miss one, follow the specific instructions provided by your clinical trial coordinator.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Linifanib is an investigational drug and is only available through registered clinical trials. Always consult with a licensed oncologist or healthcare professional regarding your specific diagnosis and treatment options. This content reflects data available as of 2026.